Researchers from Israel told a panel of US vaccine experts weighing a potential COVID-19 booster dose from Pfizer Inc. and BioNTech SE on Friday that it’s unclear how long the benefit of such a shot would last.
A big part of the case for booster shots is data from Israel showing that, in the short term, a third dose of the vaccine dramatically lowered infections and severe illness in the short term in people over age 60 and older.
However, it isn’t yet clear whether the enhanced protection boosters could provide would be short-lived, or if the benefit would be lasting.
When asked by members of a Food and Drug Administration advisory panel whether more shots would be needed to keep Covid-related illness away, the Israeli scientists said it was simply too soon to know.
“This is very early, we can’t really tell,” said Sharon Alroy-Preis from the Israel Ministry of Health. “It is not really clear where this is going.”
Sense of Smell: Most Rapid Warning System
Did Venus Ever Have Oceans?
Floods, landslides kill 116 in India and Nepal
Grenade targets Taliban vehicle in Afghan capital: Officials
Qatar, WHO, FIFA team up for ‘healthy and safe’ World Cup
Science7 days ago
Star Trek’s William Shatner blasts into space
Canada1 week ago
Photos of John Lennon, Yoko Ono’s Bed-in for Peace protest part of Vancouver gallery exhibit
Europe1 week ago
Russian plane crashes, killing 19 and injuring three
Health5 days ago
U.S. FDA panel endorses booster shot for J&J COVID-19 vaccine
Europe5 days ago
Protests greet debut of Italy’s workplace COVID-19 pass rule
Asia5 days ago
Suicide attack on Shiite mosque in Afghanistan kills 47
U.S3 days ago
Biden: ‘Democracy survived’ U.S. Capitol riot because of police
Canada7 days ago
Canada-U.S. will reopen land border to fully vaccinated visitors in November